Clinical trials: Quantiferon-CMV
Cytomegalovirus Infections
Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive
The purpose of this study is to determine the sensitivity and specificity of QuantiFeron® and ImmuKnow® in combination for early detection of patients who will develop CMV infection in lung transplant patients with CMV-positive…
- Trial name
- REIVI (NCT02076971)
- Where
- 7 sites in Spain
- Volunteers
- 92 people
- Sponsor
- Fundacio Catalana de Pneumologia
Cytomegalovirus Infections
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up.
- Trial name
- RECOHFERRON (NCT04030676)
- Testing
- Biopsies, Blood samples
- Where
- 2 sites in France
- Volunteers
- 196 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Cytomegalovirus Infections, CMV
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation.
- Conditions
- Cytomegalovirus Infections, CMV, Kidney Transplant Infection
- Trial name
- NCT03858907
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- University of Sao Paulo General Hospital
Cytomegalovirus Viraemia
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis.
- Trial name
- Q-CMV (NCT02370758)
- Testing
- Valganciclovir or Ganciclovir
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
Quantiferon-CMV, Cytomegalovirus Infections
Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients
Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in kidney transplant recipients and hemodialysis patients, comparison to control patients.
- Conditions
- Quantiferon-CMV, Cytomegalovirus Infections, Kidney Transplant Infection, Hemodialysis
- Trial name
- Quantiferon (NCT03916497)
- Testing
- Quantiferon CMV
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Cytomegalovirus Viraemia
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ…
- Trial name
- QFT-CMV (NCT02784756)
- Testing
- Quantiferon-CMV assay
- Where
- 6 sites in Canada, Spain
- Volunteers
- 134 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
CMV Specific Immune Response, Kidney Transplant
Risk Factors Associated With the Absence of CMV-specific Cellular Immune Response in the Early Post-transplant Period in Low-risk CMV-seropositive Kidney Transplant Recipients
The goal of this observational study is to identify risk factors associated with the absence of CMV-specific cellular immune response in low-risk CMV-seropositive kidney transplant recipients in the early post-transplant period.
- Conditions
- CMV Specific Immune Response, Kidney Transplant, Kidney Transplant Recipient, CMV Reactivation
- Trial name
- PREDICOR (NCT07621835)
- Where
- Spain
- Volunteers
- 236 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Infections, Heart Transplantation
Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)
Context Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. Most of available treatment display adverse effects that limit their use.
- Conditions
- Cytomegalovirus Infections, Heart Transplantation, Kidney Transplantation, Lung Transplantation
- Trial name
- QUANTIFOT (NCT06341543)
- Testing
- Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes)., Communication of the result of the QF-CMV to the clinician in charge
- Where
- France
- Volunteers
- 288 people
- Sponsor
- University Hospital, Grenoble
CMV
Clinical Evaluation of the QuantiFERON CMV Assay
Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
- Trial name
- NCT03502161
- Testing
- QuantiFERON CMV Assay
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Renal Transplant Recipient, Immunized Against the Cytomegalovirus
Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D + and D-25% R + develop CMV.
- Trial name
- QUANTIC-R+ (NCT02064699)
- Testing
- CMV Infection
- Where
- 12 sites in France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Limoges